Plaque psoriasis and psoriatic arthritis: trials to watch in 2022
Four Phase II and III trials in plaque psoriasis or psoriatic arthritis have results expected in 2H 2022, and five Phase III studies have expected completions.
By
William Newton
William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, rare diseases, and the central nervous system. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
Latest articles
All Articles
Aristea contemplates Phase III design for rare skin disease drug
As Aristea develops a palmoplantar pustulosis treatment, US and European regulators indicate different primary endpoint preferences.
By
Fauci: long Covid-19 trial endpoints ‘absolutely have to be standardised’
Clinical Trials Arena asks Dr Anthony Fauci about the biggest challenges to selecting long Covid-19 trial endpoints during a…
By
Parkinson’s disease: major drug trial results to watch in 2022
Four clinical trials in Parkinson’s disease with readouts the second half of 2022 target motor symptom fluctuations and cognitive…
By
‘How badly does it hurt?’ Challenges of measuring pain in clinical trials
Mapping Endpoints: Most clinical trials for pain still use a zero-to-ten scale as a primary endpoint. Experts are on…
By
How oncology clinical trials can use data to dig deeper on diversity
This year’s ASCO meeting highlighted the need to boost diversity in cancer studies. Experts tell Clinical Trials Arena how…
By
Parkinson’s disease: Cerevance outlines Phase II/III trial planned for Q1 2023
Cerevance CMO Jordan Dubow shares exclusive details on the first of two planned registrational trials in Parkinson’s disease.
By
Dengue fever: the urgent hunt for antivirals and vaccines
There are 100–400 million Dengue fever infections each year, and cases are quickly rising. How can manufacturers overcome obstacles…
By
Intrommune previews Phase II trial design for peanut allergy toothpaste
Intrommune CEO Michael Nelson details plans for a Phase II trial in children with peanut allergies slated for late…
By